We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT02157935
Previous Study | Return to List | Next Study

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease (RISE)

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT02157935
First Posted: June 6, 2014
Last Update Posted: November 7, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AstraZeneca
  Purpose
Comparing the efficacy of Symbicort® pMDI and Formoterol Turbuhaler in reducing exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).

Condition Intervention Phase
COPD Patients Drug: Symbicort Drug: Formoterol turbohaler Other: Placebo for Symbicort pMDI Other: Placebo for Formoterol Turbohaler Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® Pressurized Metered-Dose Inhaler (pMDI) 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in Cronic Obstructive Pulmonary Disease (COPD) Patients.

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The Rate of Moderate and Severe COPD Exacerbations Defined as: Worsening of ≥2 Major Symptoms or Worsening of 1 Major Symptom Together With ≥1 Minor Symptom for ≥2 Consecutive Days [ Time Frame: Randomization at Week 0 to End of Treatment (EoT) W 26 ]

    The annual COPD exacerbation rate was analyzed and compared between two arms.

    Annual exacerbation rate for each subject is defined as number of exacerbations divided by duration of randomized treatment period in years.

    The annual COPD exacerbation rate of Symbicort group was compared with annual rate of Formoterol group. The rate ratio of Symbicort vs. Formoteroal was assessed by a negative binomial model.

    Exacerbations, that met the modified Anthonisen criteria and duration ≥2 days were classified as moderate and severe exacerbations.

    Moderate exacerbation: treatment of symptoms with systemic corticosteroids (≥3 days) and/or antibiotics.

    Severe exacerbation: symptoms that require hospitalization (including >24 hours in ED/urgent care setting).



Secondary Outcome Measures:
  • Number of Patients With Moderate or Severe COPD Exacerbation. [ Time Frame: From randomzation to EoT W 26 ]

    The number of patients who developed moderate or severe COPD exacerbation during treatment period were reported. Cox proportional hazards regression model was fitted to data to compare the two treatment arms .

    The hazard ratio and 95% CI were estimated.


  • St. George's Respiratory Questionnaire (SGRQ) [ Time Frame: From Run-in W -4 to EoT W 26 ]

    SGRQ is a standardized, self-administered tool for measuring impaired health and perceived wellbeing in respiratory diseases; a validated electronic version of the questionnaire in the relevant validated languages was used in this study.

    The questionnaire contains 50 items divided into three dimensions (Symptoms, Activity and Impact).

    Each of the three dimensions of the questionnaire is scored separately in the range from 0 to 100:

    zero (0) score indicating no impairment of quality of life.

    The total SGRQ score ranging from 0 to 100 is a summary score utilizing responses to all items calculated using weights attached to each item of the questionnaire.

    Higher scores indicate poorer health and change of 4 units in the SGRQ has been determined to be the threshold for a clinically relevant change in health status.

    The change from baseline was statistically summarized and compared between two arms in a mixed model.


  • Pre-dose/Pre-bronchodilator FEV1 at the Study Site [ Time Frame: From Run-in W -4 to EoT W 26 ]
    FEV1 from pre-dose spirometry is a measurement of lung function. The change from baseline on pre-dose FEV1 was summarized and compared between Symbicort and Formoterol groups using a mixed model.

  • Total Rescue Medication Use (Average Puffs/Day) [ Time Frame: From Run-in W -4 to EoT W 26 ]

    Use of rescue medication is a measure of symptoms that need to be treated with a short-acting bronchodilator.

    The average daily use across the observation period was used for analysis. Change from baseline was summarized and compared between two arms using a mixed model.


  • Nights With Awakening Due to COPD [ Time Frame: From Run-in W -4 to EoT W 26 ]

    Nighttime awakening due to COPD symptoms correspond to the severity of nocturnal symptoms from COPD.

    The average number of awakening per night over the treatment period was analyzed. It was derived as the number of night with awakening divided by the total number of nights with data in the recording period. Change from baseline period on awakening was summarized and compared between two arms using a mixed model.



Enrollment: 2026
Actual Study Start Date: June 27, 2014
Study Completion Date: February 8, 2016
Primary Completion Date: February 8, 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Symbicort pMDI
Symbicort pMDI, budesonide/formoterol, 160/4.5 μg x 2 actuations BID, for oral inhalation
Drug: Symbicort
Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses
Other: Placebo for Symbicort pMDI
pMDI, aerosol for oral inhalation, placebo, 120 doses
Active Comparator: Formoterol Turbuhaler
Formoterol Turbuhaler, 4.5 μg x 2 actuations BID, for oral inhalation
Drug: Formoterol turbohaler
Formoterol Turbuhaler 4.5 μg x 2 actuations BID, for oral inhalation, 60 doses
Other: Placebo for Formoterol Turbohaler
PLacebo powder for oral inhalation, 60 doses

Detailed Description:
A Phase IIIB, 6-Month, Double-blind, Double-dummy, Randomized, Parallel-group, Multicenter Exacerbation Study of Symbicort® pMDI 160/4.5 μg x 2 Actuations Twice-daily Compared to Formoterol Turbuhaler 4.5 μg x 2 Inhalations Twice-daily in COPD Patients.
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   40 Years to 95 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

3. A current clinical diagnosis of COPD with COPD symptoms for more than 1 year, according to the GOLD guidelines.

4. Current or previous smoker with a smoking history equivalent to 10 or more pack years (1 pack year = 20 cigarettes smoked per day for 1 year).

5. Post-bronchodilator FEV1/forced vital capacity (FVC) <0.7 (70%) and FEV1 ≤70% of predicted normal (PN) value.

6. Documented use of a short-acting inhaled bronchodilator (β2-agonists or anticholinergics) as rescue medication within 6 months prior to study start.

7. A score of ≥2 on the modified medical research council (MMRC) dyspnea scale. 8. Documented history of ≥1 moderate or severe COPD exacerbation(s) that required treatment with systemic (oral, IM, IV) corticosteroids (a minimum 3 day course of an oral corticosteroid treatment or single depot corticosteroid injection), or hospitalization (defined as an inpatient stay or >24 hour stay in an observation area in the emergency department or other equivalent facility depending on the country and healthcare system) within 2-52 weeks before Visit 1 (i.e., not within the 14 days prior to Visit 1). A history of an exacerbation treated exclusively with antibiotics will not be considered adequate.

Exclusion Criteria:

  1. A history of asthma at or after 18 years of age.
  2. Subjects with significant or unstable ischemic heart disease, arrhythmia, cardiomyopathy, heart failure (including significant cor pulmonale), uncontrolled hypertension as defined by the Investigator, or any other relevant cardiovascular disorder as judged by the Investigator.
  3. Known homozygous alpha-1 antitrypsin deficiency.
  4. Any significant disease or disorder (e.g., gastrointestinal, liver, renal, neurological, musculoskeletal, endocrine, metabolic, malignant, psychiatric, major physical impairment) which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, or influence the results of the study, or the subject's ability to participate in the study.
  5. A history of malignancy (except basal cell carcinoma) within the past 5 years.
  6. Active tuberculosis, lung cancer, bronchiectasis, sarcoidosis, lung fibrosis, primary pulmonary hypertension, interstitial lung disease, or other active pulmonary diseases.
  7. Subjects who have needed additions or alterations to their usual maintenance or change in formulation of rescue therapy for COPD due to worsening symptoms within the 14 days prior to Visit 1 and up to Visit 3.
  8. CXR (frontal and lateral) with suspicion of pneumonia or other condition/abnormality that will require additional investigation/treatment, or put the subject at risk because of participation in the study.
  9. Risk factors for pneumonia: immune suppression (HIV, lupus) or other risk for pneumonia (e.g. neurological disorders affecting control of the upper airway, such as Parkinson's disease, myasthenia gravis, etc.).
  10. Pneumonia not resolved within 14 days of Visit 1.
  11. Moderate or severe COPD exacerbation that has not resolved within 14 days prior to Visit 1 or a moderate or severe COPD exacerbation that occurs between Visit 1 and Visit 2.
  12. Long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day.
  13. Subjects who are currently in the intensive rehabilitation phase or scheduled to begin new participation (intensive rehabilitation phase) in a pulmonary rehabilitation program during the study or have started a new pulmonary rehabilitation program within 60 days of Visit 1. Subjects in the maintenance phase of pulmonary rehabilitation program are not excluded.
  14. Treatment with oral, parenteral, or intra-articular corticosteroids within 4 weeks prior to Visit 1.
  15. Omalizumab or any other monoclonal or polyclonal antibody therapy taken for any reason within 6 months prior to Visit 1.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02157935


  Show 373 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Gary T Ferguson, MD Pulmonary Research Insititute of Southeast Michigan
  More Information

Additional Information:
Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT02157935     History of Changes
Other Study ID Numbers: D589UC00001
First Submitted: June 5, 2014
First Posted: June 6, 2014
Results First Submitted: December 15, 2016
Results First Posted: June 12, 2017
Last Update Posted: November 7, 2017
Last Verified: October 2017

Keywords provided by AstraZeneca:
COPD, turbuhaler, pMDI

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Respiratory Tract Diseases
Formoterol Fumarate
Budesonide, Formoterol Fumarate Drug Combination
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Adrenergic beta-2 Receptor Agonists
Adrenergic beta-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action